|
Jun 2
|
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
|
|
May 31
|
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
|
|
May 30
|
Zai Lab Announces Participation in Investor Conferences in June 2025
|
|
May 10
|
Zai Lab First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Mar 14
|
Is Zai Lab Limited (ZLAB) the Best Performing Growth Stock in 2025?
|
|
Mar 14
|
Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer
|
|
Mar 12
|
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
|
|
Mar 3
|
Zai Lab Announces Participation in Investor Conferences in March 2025
|
|
Mar 2
|
Zai Lab Limited (NASDAQ:ZLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates
|
|
Mar 1
|
Zai Lab Full Year 2024 Earnings: Beats Expectations
|
|
Feb 28
|
Zai Lab Ltd (ZLAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Path to Profitability
|
|
Feb 27
|
China Biotech's Sales Jump 66% But Bottom Line Misses Views
|
|
Feb 27
|
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
|
|
Feb 26
|
Is Zai Lab Limited (ZLAB) the Best Performing Mid Cap Stock to Buy According to Analysts?
|
|
Feb 24
|
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?
|
|
Feb 19
|
High Growth Tech Stocks To Watch In February 2025
|
|
Feb 17
|
With 73% ownership in Zai Lab Limited (NASDAQ:ZLAB), institutional investors have a lot riding on the business
|
|
Sep 27
|
High Growth Tech Stocks To Watch In September 2024
|
|
Sep 27
|
Zai Lab Limited (ZLAB) Surges 11.1%: Is This an Indication of Further Gains?
|
|
Sep 17
|
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
|